News

December 7, 2016

The Lancet Publishes Data from Phase 2, Open-Label Trial of Spinraza (Nusinersen) in Infants

Today, Lancet published results from the Phase 2, open-label trial of nusinersen (Spinraza) in infants. This trial initiated in 2013, and patients continue to receive the drug. 

The results show that infants as young as five weeks old with the most severe form of spinal muscular atrophy (SMA) - a leading genetic cause of infant...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

December 6, 2016

The Miller McNeil Woodruff Foundation Makes a Generous Contribution to Cure SMA

The Miller McNeil Woodruff Foundation Makes a Generous Contribution to Cure SMA

The Miller McNeil Woodruff Foundation awarded $87,000 to Cure SMA, in order to further research that will lead to a treatment and cure for SMA. Their gift will also help fund continued advocacy and awareness intiatives.

The generous donation is made each year by Patrick...

READ MORE   |  

Topics: Community & Awareness, Front Page News

December 5, 2016

Cure SMA-Funded Researcher, Chad Heatwole, Publishes Paper on Clinical Trial Outcomes in Adults with SMA

Cure SMA-Funded Researcher, Chad Heatwole, Publishes Paper on Clinical Trial Outcomes in Adults with SMA

Cure SMA-funded researcher, Chad Heatwole, and his team, have published a paper, "What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients".

This project was a pilot study funded by a grant from Cure SMA,...

READ MORE   |  

Topics: Research, Front Page News

Items 22 - 24 of 311  Previous12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software